Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Celgene synthesizes new CKI-alpha degradation inducers

Dec. 22, 2020

FDA approves Xpovio for multiple myeloma after at least one prior therapy

Dec. 21, 2020

LACEWING study of Xospata in FLT3mut+ AML does not meet primary endpoint

Dec. 21, 2020

FDA approves Orgovyx for advanced prostate cancer

Dec. 21, 2020

Tumors, metastases activate mTOR in different ways

Dec. 21, 2020

Preliminary phase I/II data for ZN-c5 monotherapy in ER-positive/HER2-negative breast cancer

Dec. 21, 2020

Korea Pharma describes JAK1 inhibitors

Dec. 21, 2020

Discovery of new PDIA1 inhibitor with antitumor activity in models of multiple myeloma

Dec. 21, 2020

DZD-4205 demonstrates efficacy in phase I/II JACKPOT8 study in PTCL

Dec. 21, 2020

First-in-human data presented for AB-928 with or without IPI-549 in patients with cancer

Dec. 18, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....